Clinical Analysis of Risk Factors for Recurrence in Patients with Chronic Subdural Hematoma Undergoing Burr Hole Trephination

Seong Il Jeong, MD, Si On Kim, MD, Yu Sam Won, MD, Young Joon Kwon, MD, and Chun Sik Choi, MD
Department of Neurosurgery, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, Korea

Objective: Chronic subdural hematoma (CSDH) is one of the most frequent types of intra-cranial hemorrhages usually associated with trauma. Surgical treatment is the treatment of choice and burr hole trephination (BHT) is widely performed. The recurrence rate in the patients with CSDH is 3.7–30%. This study investigated the risk factors associated with the recurrence of patients with CSDH who underwent BHT.

Methods: One hundred twenty-five patients with CSDH underwent BHT. Eight of 125 patients (6.4%) underwent reoperation for recurrent CSDH. We retrospectively analyzed demographic, clinical and radiological findings, catheter tip location and drainage duration as the risk factors for the recurrence of CSDH.

Results: Recurrence of CSDH in the high- or mixed-density groups was significantly higher than those in the low- or iso-density groups ($p<0.001$). Placement of catheter tip at the temporoparietal area was associated with a significantly higher recurrence rate of CSDH than placement at the frontal area ($p=0.006$) and the brain re-expansion rate (BRR) was much lower than placement at the frontal area ($p<0.001$).

Conclusion: The operation may be delayed in high- and mixed-density groups, unless severe symptoms or signs are present. In addition, placing the catheter tip at the frontal area helps to reduce the incidence of postoperative recurrence of CSDH and to increase the BRR.

KEY WORDS: Chronic subdural hematoma · Recurrence · Catheter tip location · Computed tomography.
niotomy, and capsulectomy, were excluded; likewise, double BHT on one side was also excluded. In addition, to block an additional influence on the recurrence of CSDH, we excluded the patients who received anti-coagulant agents, hemodilysis or cerebrospinal fluid shunt surgery. Consequently, the data of the total of 125 patients were used.

Burr holes were trephined at the region of maximal hematoma thickness on brain computed tomography (CT). CSDHs were evacuated and washed out by irrigation with a warm physiological saline solution in all patients. After the surgery, the drainage system was fixed at the level of tragus to prevent rapid drainage of CSDH and the height was changed according to the amount of drainage. Bed rest was recommended until the drainage catheter was removed. Prophylactic antibiotics were used regularly up to 3 days, unless postoperative wound infection occurred. Follow-up brain CT was performed in all patients. If the midline shift did not exist anymore, or thickness of subdural space was less than 5 mm, we concluded that brain expansion occurred and that resolution of hematoma was complete. The recurrence of CSDH was defined as re-accumulation of the hematoma on brain CT obtained within 3 months postoperatively along with the reappearance of neurological symptoms including cognitive dysfunction, hemiparesis or headache.2,1,15

We retrospectively analyzed the data to establish whether the clinical and radiologic factors, as well as catheter tip location and drainage duration were associated with the recurrence of CSDH. We examined clinical factors of age, sex, history of head trauma, preoperative Glasgow Coma Scale, medication history, laboratory characteristics and underlying diseases including cerebrovascular disease and diabetes (Table 1 and 2). The examined radiographic factors were preoperative hematoma density in brain CT, hematoma volume, location, midline shift (less than or more than 10 mm), postoperative air in the subdural space and the brain re-expansion rate (BRR)(Table 3).

*Brain re-expansion rate (BRR)=1-[(the postoperative volume of the residual hematoma)/(the preoperative volume of the hematoma)]

The density of hematoma was divided into four categories: high-density (more than 24 Hounsfield units, HU), isodensity (14–24 HU), low-density (4–14 HU) and mixed-density.
TABLE 3. The relationship between the radiologic factors and the recurrence of CSDH in 125 patients

| Hematoma location (%) | RG (n=8) | NRG (n=117) | Total (n=125) | p-value |
|-----------------------|----------|-------------|---------------|---------|
| Right                 | 2 (25.0) | 30 (25.6)   | 32 (25.6)     |         |
| Left                  | 3 (37.5) | 61 (52.1)   | 64 (51.2)     |         |
| Ipsilateral           | 5 (62.5) | 91 (77.8)   | 96 (76.8)     | 0.386   |
| Bilateral             | 3 (37.5) | 26 (22.2)   | 29 (23.2)     |         |
| Midline shift (mean ± SD, mm)* | 10.48 ± 3.52 | 9.39 ± 4.43 | 9.45 ± 4.38 | 0.592 |
| < 10 mm (%)           | 1 (20.0) | 54 (45.9)   | 55 (42.7)     | 0.160   |
| ≥ 10 mm (%)           | 4 (80.0) | 37 (40.7)   | 41 (37.3)     |         |
| Hematoma density (%)  |          |             |               | <0.001  |
| Low                   | 0 (0)    | 37 (31.6)   | 37 (29.6)     |         |
| Iso                   | 0 (0)    | 55 (47.0)   | 55 (44.0)     |         |
| High                  | 5 (62.5) | 17 (14.5)   | 22 (17.6)     |         |
| Mixed                 | 3 (37.5) | 8 ( 6.8)    | 11 ( 8.8)     |         |
| Air collection in subdural space (%) |          |             |               | 1.000   |
| < 10 cc               | 6 (75.0) | 86 (73.5)   | 92 (73.6)     |         |
| 10–50 cc              | 2 (25.0) | 25 (21.4)   | 27 (21.6)     |         |
| ≥ 50 cc               | 0 (0)    | 6 ( 5.1)    | 6 ( 4.8)      |         |
| BRR (mean ± SD)       | 0.59 ± 0.19 | 0.69 ± 0.18 | 0.68 ± 0.18 | 0.116   |

*midline shift was surveyed in the group of patients with ipsilateral hematoma (n=96). RG: recurrence group, NRG: non-recurrence group, BRR: brain re-expansion rate, CSDH: chronic subdural hematoma.

Figure 1. Brain CT showing classification of hematoma density. A: Low-density (4-14 HU). B: Iso-density (14-24 HU). C: High-density (>24 HU). D: Mixed-density. HU: Hounsfield unit.

Hematoma volume and thickness were examined, and were classified according to the criteria of volume of 120 cc and thickness of 20 mm. In this study, the brilliance workspace program of BR64 CT (Philips Medical Systems, Amsterdam, the Netherlands) was used to investigate hematoma volume. The amount of the air in the subdural space after surgery was classified into three categories: <10 cc, 10–50 cc and >50 cc.

We investigated whether catheter tip location or drainage duration influenced recurrence of CSDH (Table 4). The location of the drainage catheter tip was classified into two subgroups: frontal area and temporoparietal area (Figure 2). Postoperative brain CT scans were obtained in all patients on the second day after the surgery. When there was no deviation in the midline and the thickness of subdural space was <5 mm, we concluded that the brain was fully expanded and then removed the drainage catheter. In case when thickness of subdural space was >5 mm, the drainage catheter was kept an additional 2–3 days and then removed. The period of drainage was based on the removal time and classified into two subgroups: <2 days and ≥2 days.

Statistical analyses included independent t-test and Fisher exact test to assess the relationship between each parameter and the risk factors on the recurrence of CSDH. For all analyses, p<0.05 was considered to be statistically significant.

Results

One hundred twenty five patients were recruited. Patient clinical characteristics are summarized in Table 1 and 2. The mean age was 69.37 years; 92 patients (73.6%) were males and 33 (26.4%) females. Recurrence of CSDH oc-
Risk Factors for Recurrence of Chronic Subdural Hematoma

| TABLE 4. The relationship between the location of catheter tip and drainage duration and the recurrence of CSDH in 125 patients |
|-----------------------------------------------------------|
| RG (n=8) | NRG (n=117) | Total (n=125) | p-value |
|-----------------|-----------|--------------|---------|
| Drainage duration (mean ± SD) | 2.88 ± 0.84 | 2.63 ± 0.93 | 2.65 ± 0.93 | 0.476 |
| <2 days (%) | 3 (37.5) | 65 (55.6) | 68 (54.4) | 0.467 |
| ≥2 days (%) | 5 (62.5) | 52 (44.4) | 57 (45.6) | |
| Location of catheter tip (%) | | | | 0.006 |
| Frontal | 2 (25.0) | 88 (75.2) | 90 (72.0) | |
| Temporoparietal | 6 (75.0) | 29 (24.8) | 35 (28.0) | |

RG: recurrence group, NRG: non-recurrence group, CSDH: chronic subdural hematoma

FIGURE 2. Skull radiographs showing catheter tip position after BHT. The location was classified into two areas: frontal area (A, B) and temporoparietal area (C, D). BHT: burr hole trephination.

In three patients (37.5%). There was no statistically significant difference between the ipsilateral and bilateral recurrence groups (p=0.386). Of 96 ipsilateral CSDH patients, CSDH with midline shift ≥10 mm showed higher recurrence rate than those with midline shift <10 mm, however the difference was not statistically significant (p=0.592). The volume and the thickness of hematoma were not associated with the recurrence of CSDH (p=0.479 and p=0.440, respectively).

Hematoma density on CT scans were high- or mixed-density in 24.4%, iso-density in 44% and low-density in 29.6%. High- or mixed-density groups were significantly more related with the recurrence of CSDH than iso-density or low-density groups (p<0.001). The relationship between the amount of air in the subdural space and the recurrence was not statistically significant (p=1.000)(Table 3). BRR of the recurrence and non-recurrence groups was 0.59 ± 0.19 and 0.69 ± 0.18, respectively. BRR of the non-recurrence group was higher, but the difference did not reach statistical significance (p=0.116)(Table 3).

Finally, we investigated whether the catheter tip location or drainage duration influenced recurrence of CSDH (Table 4). The mean duration of postoperative drainage in the recurrence group was longer than that of the non-recurrence group, but there was no statistically significant difference between the duration of drainage and the recurrence of CSDH (p=0.467). Regarding the location of catheter tip, temporoparietal location showed high recurrence rate compared to frontal location (17.1% versus 2.2%). The relationship between the location of catheter tip and the recurrence of CSDH was statistically significant (p=0.006), as was the relationship between the location of catheter tip and the BRR was
statistically significant ($p<0.001$)(Table 5).

Discussion

As a relatively common brain disease occurring due to a direct or an indirect trauma of brain resulting in the rupture of parasagittal bridging vein, CSDH shows good treatment outcomes. Precipitating factors are intracranial hypotension, brain atrophy, hematologic disorder, deformed skull and cerebrospinal fluid fistula. The hematoma may either resorb spontaneously or gradually increase in size resulting in a CSDH. The volume of CSDH gradually increases because of repeated micro-hemorrhages. This results in the increase of intracranial pressure and leads to the symptoms of CSDH. In our study, we performed BHT. Of the various surgical treatments, BHT is the simplest and most widely-used treatment for the removal of CSDH. We analyzed risk factors of recurrence according to clinical factors, radiological factors and catheter tip location and drainage duration.

Old age, brain atrophy, poor health status at the time of admission, high bleeding tendency, kidney and liver disease, chronic alcoholism, diabetes mellitus, epilepsy, dementia and intracranial hypotension due to cerebrospinal fluid shunt are reported to be relevant factors of CSDH recurrence. More recently, antiangiogenic activity of the ACE inhibitors on blood vessels was reported to reduce the rate of recurrence in CSDH, as well as the levels of vascular endothelial growth factor within the hematoma. Anti-platelet agents have been suggested risk factors for occurrence of CSDH, but a number of literature reviews have mentioned that anti-platelet agents are not associated with CSDH recurrence. In our study, in 35 patients using anti-platelet agents, only four had recurrence. We also established that there was no statistically significant relationship between the use of anti-platelet agents and the recurrence of CSDH.

In line with the theoretical beneficial mechanism of action, namely, the anti-inflammatory and anti-angiogenic effects, corticosteroids are often used in CSDH treatment. Accordingly, Berghauer Pont et al. mentioned that the use of corticosteroids lowers the recurrence of CSDH. However, our study revealed no relationship between the use of corticosteroids and the recurrence of CSDH. In addition, we investigated old age (over 70 years), hypertension, diabetes mellitus, as well as cerebrovascular and cardiovascular disease and the recurrence of CSDH, and found no statistically significant relationships. In the examination of the relationship between the use of ACE inhibitors and the recurrence of CSDH, these two factors were not found to be associated.

Radiological factors that have been reported to be associated with the recurrence of CSDH include a large number of hematomas, bilateral hematoma, hematoma formation within the outer membrane, the amount of air in the postoperative subdural space and high and mixed density of hematomas in brain CT. CSDH is classified according to the density of hematomas. The density of CSDH reflects the proportion of fresh blood clots in the hematoma cavity, and a high proportion of fresh blood clots means the active growth of blood vessels into the membrane of CSDH. Therefore, high density of hematoma indicates that the neocapillary network actively forms into the membrane of hematoma and indicates the likelihood of hematoma re-bleeding at the same time. Higher density of hematoma has been related to a higher rate of CSDH recurrence. However, contradictory results have been presented, which could be due to the subjectivity of the density of hematoma classification. The incidence of re-bleeding was reportedly lower in the mixed and the layered density. However, Ohba et al. reported no relationship between the density of hematoma and its recurrence.

In our study, more patients displayed high- or mixed-density in the CSDH recurrence group than in the non-recurrence group, with statistical significance. This result is consistent with the previous conclusions that high density is indicative of the progress of CSDH in the acute phase and is associated with a high CSDH recurrence rate. Surgery of hematomas that were not fully developed resulted in a high recurrence of CSDH. Consequently, in cases of acute phase patients with CSDH showing high and mixed density on brain CT, surgery should be delayed, unless severe symptoms are present, and undertaken at a later stage when CSDH appears as iso- or low-density on brain CT. Doing so would reduce the recurrence of CSDH.

We investigated the relationship between postoperative BRR and the recurrence of CSDH. Based on several studies, CSDH is expected to be more likely to recur due to the reformation of subdural hematoma when subdural space continuously existed or the re-expansion of brain was delayed after BHT. Presently, BRR was higher in the non-recurrence group than in the recurrence group, but this relationship was not statistically significant.

Several studies have shown that the existence of residual air in the postoperative subdural space is associated with the recurrence of hematoma or brain re-expansion. In addition, air influx into subdural space during surgery prohibits brain re-expansion and then raises the recurrence of CSDH.
Our study found no relationship between the amount of postoperative subdural air and the recurrence of CSDH. In addition, the relationship between the recurrence of CSDH and the degree of midline shift was analyzed: no statistically significant meaning was evident.

Regarding treatment for the recurrence of CSDH, inadequate drainage and early surgery before the full liquefaction of hematoma have been reported. In addition, a longer drainage period corresponds to less frequent recurrence of CSDH. For duration drainage <48 hours, the recurrence rate of CSDH exceeds 10%. According to Yu et al., while the recurrence rate of CSDH in postoperative patient group having more than 3 days of drainage duration was only 1.3%, the recurrence rate of CSDH in the postoperative patient group having less than 3 days of drainage duration was 16.3%. Thus, this study insisted on at least 3 days of drainage duration. However, there was no significant difference between the patients group having less than 2 days of drainage duration and the patients group having more than 2 days of drainage duration in our study.

According to Choi et al., the rate of re-formation in hematoma varies depending on the location of burr hole, and drilling burr hole in the frontal bone produces a better result than in the parietal bone. In addition, Nakaguchi et al. and Kim et al. reported that there was less recurrence of CSDH in cases where the drainage catheter tip was placed in the frontal area. In our study, placement of the catheter tip in the temporoparietal area was associated with higher recurrence of CSDH than placement in the frontal area: this difference was statistically significant. In addition, BRR was higher in cases where the catheter tip was placed in the frontal area compared to temporoparietal area placement, and the difference was also statistically significant.

Although the significant relationship between BRR and recurrence rate of CSDH was not verified in this study, the BRR in the recurrence group was lower than that in the non-recurrence group, and the case of placing the catheter tip into the frontal area showed a significantly higher BRR compared to the temporoparietal area. Based on this study, further research on the relationship between BRR and the recurrence of CSDH is needed.

**Conclusion**

Surgery should be delayed for patients with CSHD showing high- or mixed-density on brain CT until they reach low-density hematoma unless the symptoms are already severe. In addition, placing the catheter tip to the frontal area may be helpful in reducing postoperative recurrence of CSHD and increasing the BRR.

The authors have no financial conflicts of interest.

**REFERENCES**

1. Adhiyaman V, Asghar M, Ganeshram KN, Bhownick BK. Chronic subdural haematoma in the elderly. Postgrad Med J 78:71-75, 2002
2. Ahn SY, Kim JH, Ha SK, Kim JH, Kwon TH, Park YK, et al. Clinical analysis of risk factors associated with the recurrence of chronic subdural hematoma. J Korean Neurotraumatol Soc 7:68-73, 2011
3. Berghauser Pont LM, Dirven CM, Dippel DW, Verweij BH, Dammers R. The role of corticosteroids in the management of chronic subdural hematoma: a systematic review. Eur J Neurol 19:1397-1403, 2012
4. Cenic A, Bhandari M, Reddy K. Management of chronic subdural hematoma: a national survey and literature review. Can J Neurol Sci 32:501-506, 2005
5. Choi CH, Moon BG, Kang HI, Lee SJ, Kim JS. Factors affecting the reaccumulation of chronic subdural hematoma after burr-hole trephination and closed-system drainage. J Korean Neurosurg Soc 38:192-198, 2004
6. El-Kadi H, Miele VJ, Kaufman HH. Prognosis of chronic subdural hematomas. Neurosurg Clin N Am 11:553-567, 2000
7. Fogelholm R, Heiskanen O, Waltimo O. Chronic subdural hematoma in adults. Influence of patient’s age on symptoms, signs, and thickness of hematoma. J Neurosurg 42:43-46, 1975
8. Frati A, Salvati M, Mainiero F, Ippoliti F, Rocchi G, Raco A, et al. Inflammation markers and risk factors for recurrence in 35 patients with a posttraumatic chronic subdural hematoma: a prospective study. J Neurosurg 100:24-32, 2004
9. Fukuhara T, Gotoda M, Asari S, Ohmoto T, Akioka T. The relationship between brain surface elastance and brain reexpansion after evacuation of chronic subdural hematoma. Surg Neurol 45:570-574, 1996
10. Kang HL, Shin HS, Kim TH, Hwang YS, Park SK. Clinical analysis of recurrent chronic subdural hematoma. J Korean Neurosurg Soc 40:262-266, 2006
11. Kang MS, Koh HS, Kwon HJ, Choi SW, Kim SH, Youn JY. Factors influencing recurrent chronic subdural hematoma after surgery. J Korean Neurosurg Soc 41:11-15, 2007
12. Kim HS, Heo W, Cha JH, Song JS, Rhee DY. Factor affecting recurrence of chronic subdural hematoma after burr-hole drainage. Korean J Neurotrauma 8:73-78, 2012
13. Kiyimaz N, Yilmaz N, Mucucu C. Controversies in chronic subdural hematoma: continuous drainage versus one-time drainage. Med Sci Monit 13:CR240-CR243, 2007
14. Ko BS, Lee JK, Seo BR, Moon SJ, Kim JH, Kim SH. Clinical analysis of risk factors related to recurrent chronic subdural hematoma. J Korean Neurosurg Soc 43:11-15, 2008
15. Kong WK, Kim BC, Choi KT, Hong SK. Factors affecting postoperative recurrence of chronic subdural hematoma. Korean J Neurotrauma 8:122-127, 2012
16. Kostanian V, Choi JC, Liker MA, Go JL, Zee CS. Computed tomographic characteristics of chronic subdural hematomas. Neurosurg Clin N Am 11:479-489, 2000
17. Kotwica Z, Brzezinski J. Chronic subdural haematoma treated by burr holes and closed system drainage: personal experience in 131 patients. Br J Neurosurg 5:461-465, 1991
18. Kuroki T, Katsuura M, Harada N, Yamazaki T, Aoki K, Takasu N. Strict closed-system drainage for treating chronic subdural hematomat. Acta Neurochir (Wien) 143:1041-1044, 2001
19. Lee JY, Ebel H, Ernestus R, Klug N. Various surgical treatments of chronic subdural hematoma and outcome in 172 patients: is...
membranectomy necessary? Surg Neurol 61:523-527; discussion 527-528, 2004
20) Lindvall P, Koskinen LO. Anticoagulants and antiplatelet agents and the risk of development and recurrence of chronic subdural haematomas. J Clin Neurosci 16:1287-1290, 2009
21) Markwalder TM, Steinziepe KF, Rohner M, Reichenbach W, Markwalder H. The course of chronic subdural hematomas after burr-hole craniostomy and closed-system drainage. J Neurosurg 55:390-396, 1981
22) Matsumoto K, Akagi K, Abeke M, Ryujin H, Ohkawa M, Isawa N, et al. Recurrence factors for chronic subdural hematomas after burr-hole craniostomy and closed system drainage. Neurol Res 21:277-280, 1999
23) Mori K, Maeda M. Surgical treatment of chronic subdural hematoma in 500 consecutive cases: clinical characteristics, surgical outcome, complications, and recurrence rate. Neurol Med Chir (Tokyo) 41:371-381, 2001
24) Murakami H, Hirose Y, Sagoh M, Shimizu K, Kojima M, Gotoh K, et al. Why do chronic subdural hematomas continue to grow slowly and not coagulate? Role of thrombomodulin in the mechanism. J Neurosurg 96:877-884, 2002
25) Nakaguchi H, Tanishima T, Yoshimasa N. Factors in the natural history of chronic subdural hematomas that influence their postoperative recurrence. J Neurosurg 95:256-262, 2001
26) Nakaguchi H, Tanishima T, Yoshimasa N. Relationship between drainage catheter location and postoperative recurrence of chronic subdural hematoma after burr-hole irrigation and closed-system drainage. J Neurosurg 93:791-795, 2000
27) Nomura S, Kashiwagi S, Fujisawa H, Ito H, Nakamura K. Characterization of local hyperfibrinolysis in chronic subdural hematomas by SDS-PAGE and immunoblot. J Neurosurg 81:910-913, 1994
28) Obha S, Kinoshita Y, Nakagawa T, Murakami H. The risk factors for recurrence of chronic subdural hematoma. Neurosurg Rev 36:145-149; discussion 149-150, 2013
29) Oishi M, Toyama M, Tamatani S, Kitazawa T, Saito M. Clinical factors of recurrent chronic subdural hematoma. Neurol Med Chir (Tokyo) 41:382-386, 2001
30) Okada Y, Akai T, Okamoto K, Iida T, Takata H, Iizuka H. A comparative study of the treatment of chronic subdural hematoma--burr hole drainage versus burr hole irrigation. Surg Neurol 57:405-409; discussion 410, 2002
31) Rust T, Kiemer N, Erasmus A. Chronic subdural haematomas and anticoagulation or anti-thrombotic therapy. J Clin Neurosci 13:823-827, 2006
32) Sharp AA. Diagnosis and management of disseminated intravascular coagulation. Br Med Bull 33:265-272, 1977
33) Stroobandt G, Fransen P, Thauvoy C, Menard E. Pathogenetic factors in chronic subdural haematoma and causes of recurrence after drainage. Acta Neurochir (Wien) 137:6-14, 1995
34) Torihashi K, Sadamasu N, Yoshida K, Narumi O, Chin M, Yamagata S. Independent predictors for recurrence of chronic subdural hematoma: a review of 343 consecutive surgical cases. Neurosurgery 63:1125-1129; discussion 1129, 2008
35) Voelker JL. Nonoperative treatment of chronic subdural hematoma. Neurosurg Clin N Am 11:507-513, 2000
36) Weigel R, Hohenstein A, Schlickum L, Weiss C, Schilling L. Angiotensin converting enzyme inhibition for arterial hypertension reduces the risk of recurrence in patients with chronic subdural hematoma possibly by an antiangiogenic mechanism. Neurosurgery 61:788-792; discussion 792-793, 2007
37) Yamamoto H, Hirashima Y, Hamada H, Hayashi N, Origasa H, Endo S. Independent predictors of recurrence of chronic subdural hematoma: results of multivariate analysis performed using a logistic regression model. J Neurosurg 98:1217-1221, 2003
38) Yu GJ, Han CZ, Zhang M, Zhuang HT, Jiang YG. Prolonged drainage reduces the recurrence of chronic subdural hematoma. Br J Neurosurg 23:606-611, 2009